COMMUNIQUÉS West-GlobeNewswire
-
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
30/04/2024 - 07:00 -
Assemblée Générale mixte du 22 mai 2024 - Modalités de mise à disposition ou de consultation des documents préparatoires
30/04/2024 - 07:00 -
Combined General Meeting of May 22, 2024 - Availability of preparatory documents
30/04/2024 - 07:00 -
BioSenic S.A. : Information relative au nombre total de droits de vote et d’actions
30/04/2024 - 07:00 -
BioSenic S.A. : Information on the total number of voting rights and shares
30/04/2024 - 07:00 -
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
30/04/2024 - 07:00 -
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors
30/04/2024 - 08:00 -
Hydreight Achieves Record Revenue, Files Audited Financial Statements for Fiscal Year 2023
30/04/2024 - 03:00 -
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
30/04/2024 - 03:05 -
Stride Autism Centers Hosts Open House in Downers Grove, IL
30/04/2024 - 04:13 -
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
29/04/2024 - 23:30 -
BeyondSpring Files 2023 Annual Report on Form 20-F
29/04/2024 - 23:30 -
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
30/04/2024 - 00:30 -
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
30/04/2024 - 00:40 -
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
30/04/2024 - 02:00 -
Mustang Bio Announces Pricing of $4 Million Public Offering
30/04/2024 - 02:00 -
Aurora Spine Corporation Announces Fourth Quarter and Fiscal 2023 Financial Results
30/04/2024 - 02:20 -
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve
29/04/2024 - 21:30 -
Pediatric Brain Tumor Foundation celebrates FDA approval of Day One Biopharmaceuticals’ OJEMDA™, new treatment for common pediatric brain tumor type
29/04/2024 - 21:30
Pages